Cytokinetics (CYTK) Stock Forecast, Price & News

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last twelve months. There are currently 1 hold rating and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CYTK shares.
View CYTK analyst ratings or view top-rated stocks.

12 brokerages have issued twelve-month target prices for Cytokinetics' stock. Their CYTK share price forecasts range from $15.00 to $80.00. On average, they anticipate the company's stock price to reach $56.29 in the next year. This suggests a possible upside of 45.7% from the stock's current price.
View analysts price targets for CYTK or view top-rated stocks among Wall Street analysts.

Cytokinetics' stock was trading at $45.82 on January 1st, 2023. Since then, CYTK stock has decreased by 15.7% and is now trading at $38.63.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our CYTK earnings forecast.

Cytokinetics, Incorporated (NASDAQ:CYTK) posted its quarterly earnings results on Thursday, May, 4th. The biopharmaceutical company reported ($1.38) EPS for the quarter, missing analysts' consensus estimates of ($1.24) by $0.14. The biopharmaceutical company had revenue of $4.60 million for the quarter, compared to the consensus estimate of $2.50 million. Cytokinetics had a negative trailing twelve-month return on equity of 1,401.63% and a negative net margin of 439.05%. Cytokinetics's quarterly revenue was up 300.0% on a year-over-year basis. During the same period in the previous year, the business earned ($1.02) EPS.

ETFs with the largest weight of Cytokinetics (NASDAQ:CYTK) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH), ALPS Medical Breakthroughs ETF (SBIO), Global X Guru Index ETF (GURU), American Century Mid Cap Growth Impact (MID), Invesco S&P SmallCap 600 Pure Growth ETF (RZG), Invesco S&P SmallCap Momentum ETF (XSMO), SPDR S&P Biotech ETF (XBI) and Principal Healthcare Innovators ETF (BTEC).

16 employees have rated Cytokinetics Chief Executive Officer Robert I. Blum on Glassdoor.com. Robert I. Blum has an approval rating of 64% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Novavax (NVAX), Amgen (AMGN), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

Cytokinetics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (15.29%), FMR LLC (13.45%), Wellington Management Group LLP (7.87%), State Street Corp (4.97%), American Century Companies Inc. (2.80%) and Pictet Asset Management SA (2.38%). Insiders that own company stock include B Lynne Parshall, Bvf Partners L P/Il, Ching Jaw, David Cragg, Edward M Md Kaye, Fady Ibraham Malik, John T Henderson, John T Henderson, L Patrick Gage, Mark A Schlossberg, Robert I Blum, Robert I Blum, Robert Wong, Sandford D Smith, Sandford D Smith, Santo J Costa and Wendall Wierenga.
View institutional ownership trends.

Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CYTK stock can currently be purchased for approximately $38.63.

Cytokinetics (NASDAQ:CYTK) has a market capitalization of $3.69 billion and generates $94.59 million in revenue each year. The biopharmaceutical company earns $-388,950,000.00 in net income (profit) each year or ($4.58) on an earnings per share basis.

The company employs 253 workers across the globe.

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.cytokinetics.com. The biopharmaceutical company can be reached via phone at (650) 624-3000, via email at investor@cytokinetics.com, or via fax at 650-624-3010.